Montpellier, France– September 3, 2026 – Cilcare, a biotechnology company dedicated to advancing therapies and precision medicine solutions for hearing disorders, today announced the appointment of Dr. Louis Delamarre as Medical Director of Translational Research. With over a decade of experience in clinical translational research and multidisciplinary patient care, Dr. Delamarre will oversee the strategic and operational transition of Cilcare’s assets from preclinical research to clinical development.
An anesthesiologist and critical care physician, Dr. Delamarre brings a strong clinical experience gained at leading French university hospitals, including expertise in neurosurgery, interventional neuroradiology, and severe trauma care. In his new role, Dr. Delamarre will lead Cilcare’s medical and translational research strategy, supporting the advancement of the Company’s therapeutic pipeline and precision medicine programs. He will oversee observational studies designed to identify early auditory dysfunction in at-risk populations, contribute to the development and validation of innovative biomarkers, and strengthen collaborations with clinical investigators, key opinion leaders, and academic partners worldwide.
“Louis brings a unique combination of clinical expertise, scientific rigor, and translational vision,” said Celia Belline, Chief Executive Officer of Cilcare. “His appointment marks an important step in strengthening our clinical development capabilities and our ability to bridge scientific discovery with patient care. As we continue advancing our therapeutic programs and biomarker platform, Louis’ leadership will help accelerate the translation of innovation into meaningful benefits for patients living with hearing disorders.”
“I am excited to join Cilcare at such an important stage of its development,” said Dr. Louis Delamarre. “Hearing disorders remain largely underdiagnosed and undertreated despite their major impact on quality of life and healthy ageing. I look forward to working with the talented Cilcare team and our clinical and academic partners to advance innovative therapies and translational research that can improve outcomes for patients worldwide.”
Dr. Delamarre received his medical degree from Toulouse University Hospital and completed a specialization in anesthesiology and intensive care, followed by a PhD in Occupational Health and Statistics. Authors of more than 35 publications, he has been a reviewer for Intensive Care Medicine since 2024.
About Cilcare
Headquartered in Montpellier, France, with operations in Boston and Tokyo, Cilcare is a biotechnology company dedicated to developing transformative therapies for hearing disorders, including hearing loss and tinnitus. Within this rapidly evolving landscape, Cilcare has established a differentiated position through its unique perspective on hearing loss, viewing it not only as a sensory disorder, but also as a major risk factor and comorbidity for chronic inflammatory and neurodegenerative diseases.
The Company is advancing a diversified portfolio of therapeutic candidates targeting multiple biological mechanisms involved in hearing loss while applying a precision medicine approach designed to identify patient populations most likely to benefit from treatment.
By integrating proprietary multimodal auditory data, innovative biomarkers, and artificial intelligence-driven analytics, Cilcare enables patient stratification at the earliest stages of clinical development. This capability has the potential to significantly improve clinical success rates, optimize trial design, and reduce development risk.
Media Contact
Marie Peytavy-Izard
Marketing & Communication Director
marie.peytavy@cilcare.com
Â
